DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/e78176d0/emerging_pharmaceu) has announced the addition of the "Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates" report to their offering.
GBI Research's new report, Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes the overall pharmaceutical and outsourcing market structure in the Czech Republic. Further to this, the report provides competitive benchmarking for leading companies and analyzes the M&A and strategic partnerships that shape the Czech pharmaceutical market. This report is based on data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Antineoplastics and Cardiovascular Drugs Account for Approximately One-Third of the Czech Republic Pharmaceutical Market
The Czech Republic pharmaceutical market is dominated by the sales of antineoplastics and cardiovascular drugs. In 2010, antineoplastics accounted for 19% of drug consumption and cardiovascular drugs, for 15% of drugs consumption. Over the past five years spending on cancer drugs has increased significantly, from 14% in 2006, to 19% in 2010 as a result of the increased prevalence of different types of cancers in the Czech Republic.
There are currently 80,000 cancer patients in the Czech Republic and this figure is expected to reach 90,100 by 2018, leading to an increase in antineoplastic drug consumption in the coming years. The other major class of drug, cardiovascular drugs, generated a significant proportion of revenue in the Czech pharmaceutical market.
A non-linear trend has been observed in the consumption of cardiovascular drugs in recent years. In 2010, cardiovascular drug revenues constituted 15% of the pharmaceutical market. Sales of these two major classes of drugs contributed to over one-third of the Czech pharmaceutical market.
Companies Mentioned
- Quintiles
- PPD
- Covance
- Inc Research
- PAREXEL
- Chiltern
- MEDPACE
- PRA International
- CEPHA
- KCR
- A-Pharma
- EastHORN
- Prague Clinical Services
- PHARMNET
For more information visit http://www.researchandmarkets.com/research/e78176d0/emerging_pharmaceu